/ Active, not recruitingPhase 2 评价Tazemetostat联合HMPL-689治疗复发难治性淋巴瘤患者的安全性、耐受性、药代动力学和初步疗效的II期研究
[Translation] A Phase II study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of tazemetostat combined with HMPL-689 in patients with relapsed or refractory lymphoma
剂量递增阶段(IIa期):评价Tazemetostat联合HMPL-689治疗R/R淋巴瘤患者的安全性、耐受性,并确定MTD和/或RP2D
剂量扩展阶段(IIb期):评价Tazemetostat联合HMPL-689在淋巴瘤患者中的初步疗效
[Translation] Dose escalation phase (Phase IIa): Evaluate the safety and tolerability of Tazemetostat combined with HMPL-689 in the treatment of patients with R/R lymphoma, and determine the MTD and/or RP2D
Dose expansion phase (Phase IIb): Evaluate the preliminary efficacy of Tazemetostat combined with HMPL-689 in patients with lymphoma
100 Clinical Results associated with HUTCHMED (Hong Kong) Limited
0 Patents (Medical) associated with HUTCHMED (Hong Kong) Limited
100 Deals associated with HUTCHMED (Hong Kong) Limited
100 Translational Medicine associated with HUTCHMED (Hong Kong) Limited